| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/06/2005 | CN1209371C Vasoconstriction factor and preparation method as well as its application in pharmacy |
| 07/06/2005 | CN1209370C New human protein with cancer inhibiting function and its encoding sequence |
| 07/06/2005 | CN1209369C Cell death inducing protein and its coding sequence and use |
| 07/06/2005 | CN1209368C Novel acetamide derivative and use thereof |
| 07/06/2005 | CN1209363C Novel bicyclic amino-pyrazino ketone compound, its preparation method and medicinal composition having same |
| 07/06/2005 | CN1209166C Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance |
| 07/06/2005 | CN1209165C Method for cell adhesion and wound healing |
| 07/06/2005 | CN1209164C Compositions comprising DNA damaging agents and P53 |
| 07/06/2005 | CN1209163C Meningococcal vaccine and its preparing method |
| 07/05/2005 | US6914135 Kunitz domain polypeptide zkun10 |
| 07/05/2005 | US6914132 Compositions and methods for the therapy and diagnosis of lung cancer |
| 07/05/2005 | US6914129 Anti-IgE antibodies |
| 07/05/2005 | US6914127 A tetramer-free, stroma-free, crosslinked, polymerized hemoglobin from human blood; nontoxic |
| 07/05/2005 | US6914126 Crosslinking agent reacts with reactive pendant groups existing on the keratin molecules to produce biocompatible heterogenous proteinaceous networks crosslinked with the heterogenous crosslinker |
| 07/05/2005 | US6914125 Scramblase 2 |
| 07/05/2005 | US6914122 Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties |
| 07/05/2005 | US6914050 Stimulation of bone growth with thrombin peptide derivatives |
| 07/05/2005 | US6914049 IGF-binding protein-derived peptide or small molecule |
| 07/05/2005 | US6914047 Secreted protein HEMAE80 |
| 07/05/2005 | US6914046 Administering human growth hormone having a specific amino acid sequence to cancer patients who are resistant to, or at risk of developing a resistance to a NF-kappa B-activating cytotoxic molecule |
| 07/05/2005 | US6914045 Glycopeptide antibiotics |
| 07/05/2005 | US6914044 Compounds and methods for modulating cell adhesion |
| 07/05/2005 | US6913926 Use of a pituitary tumor transforming gene peptide which has the ability to regulate endogenous PTTG1 expression and/or function in a dominant negative manner |
| 07/05/2005 | US6913917 Anti-cocaine catalytic antibody |
| 07/05/2005 | US6913915 PEG-modified uricase |
| 07/05/2005 | US6913904 Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof |
| 07/05/2005 | US6913900 Plasma prekallikrein activation and kallikrein production assay |
| 07/05/2005 | US6913892 Method of obtaining compositions comprising Y4 specific compounds |
| 07/05/2005 | US6913891 Comprises myeloid terminal differentiation (MYD) polypeptide for diagnosis and treatment of leukemia and cell proliferative disorders; antisense agents |
| 07/05/2005 | US6913761 Sustained drug delivery |
| 07/05/2005 | US6913755 Amino acid substituted DNA sequences for use as vaccines against streptococcus |
| 07/05/2005 | US6913745 Passive immunization of Alzheimer's disease |
| 07/05/2005 | US6913744 Administering collagenase and other enzymes; side effect reduction |
| 07/05/2005 | CA2327439C Combination therapy for the treatment of tumors |
| 07/05/2005 | CA2298639C Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same |
| 07/05/2005 | CA2280875C Remedies for lymphocytic tumors |
| 07/05/2005 | CA2215793C Use of neuronal apoptosis inhibitor protein (naip) |
| 06/30/2005 | WO2005059719A2 Calculating confidence levels for peptide and protein identification |
| 06/30/2005 | WO2005059550A1 Dna encoding snorf138 and uses thereof |
| 06/30/2005 | WO2005059515A2 Method for treating neurological disorders |
| 06/30/2005 | WO2005059137A1 Brachyspira pilosicoli 72kda outer-membrane protein and diagnostic and therapeutic uses thereof |
| 06/30/2005 | WO2005059136A2 Dna-sequence and recombinant production of group 4 major allergens from cereals |
| 06/30/2005 | WO2005059133A2 Combination therapy associating a tgf-breta antagonist with a chemiotherapeutic agent |
| 06/30/2005 | WO2005059131A2 Protein binding miniature proteins and uses thereof |
| 06/30/2005 | WO2005059124A2 Isozyme-specific antagonists of protein kinase c |
| 06/30/2005 | WO2005059123A2 Pp2a/bgamma subunits, modulators thereof, and their uses in the treatment of mental disorders |
| 06/30/2005 | WO2005059099A2 Human ipla2t |
| 06/30/2005 | WO2005058965A1 Methods and compositions for inhibiting c-met dimerization and activation |
| 06/30/2005 | WO2005058962A1 Methods of therapy and diagnosis using targeting of cells that express bclp polypeptides |
| 06/30/2005 | WO2005058959A2 Treatment of viral infections |
| 06/30/2005 | WO2005058958A2 Novel glp-1 analogues linked to albumin-like agents |
| 06/30/2005 | WO2005058955A1 Analogues of glp-1 |
| 06/30/2005 | WO2005058954A1 Novel glp-1 compounds |
| 06/30/2005 | WO2005058953A2 Ogh fusion polypeptides and therapeutic uses thereof |
| 06/30/2005 | WO2005058939A2 Methods and compositions for inhibition of bcl6 repression |
| 06/30/2005 | WO2005058938A2 Helical synthetic peptides that stimulate cellular cholesterol efflux |
| 06/30/2005 | WO2005058930A2 Methods for production of recombinant vascular endothelial cell growth inhibitor |
| 06/30/2005 | WO2005058889A2 Biological active blood serum obtained by electrostimulation |
| 06/30/2005 | WO2005058821A1 Inhibitors of hepatitis c virus ns3/ns4a serine protease |
| 06/30/2005 | WO2005058380A1 Wound care products containing keratin |
| 06/30/2005 | WO2005058369A2 Compositions of l-caldesmon for treating viral infection |
| 06/30/2005 | WO2005058368A1 Methods and compositions for treatment of interferon-resistant tumors |
| 06/30/2005 | WO2005058366A2 Compositions comprising two different populations of polymer-active agent conjugates |
| 06/30/2005 | WO2005058358A2 Use of agents derived from ceacam1 for the treatment of inflammatory diseases |
| 06/30/2005 | WO2005058351A2 Treatment of rheumatoid arthritis with soluble fas-ligand cross-linkers |
| 06/30/2005 | WO2005058348A1 Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic |
| 06/30/2005 | WO2005058347A1 Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases |
| 06/30/2005 | WO2005058346A1 Stabilized interferon liquid formulations |
| 06/30/2005 | WO2005058345A1 A treatment for necrotizing enterocolitis |
| 06/30/2005 | WO2005058344A1 Antimicrobial composition |
| 06/30/2005 | WO2005058343A1 Bactericide against streptococcus mutans and streptococcus sobrinus |
| 06/30/2005 | WO2005058342A1 Methods and compositions for modulating ovulation |
| 06/30/2005 | WO2005058333A1 Method for obtaining a biologically active blood serum treated with electroshock and the utilization thereof |
| 06/30/2005 | WO2005058332A2 Edestin-comprising agent for substitution of blood plasma and a method of its production |
| 06/30/2005 | WO2005058314A2 Methods for reducing the effects of stress on skin condition |
| 06/30/2005 | WO2005058294A1 Copper antagonist compounds |
| 06/30/2005 | WO2005058289A1 A method of preparing intranasal dry powders inhalant of calcitonin |
| 06/30/2005 | WO2005058283A2 Stabilised compositions of factor vii polypeptides |
| 06/30/2005 | WO2005058252A2 Glp-1 pharmaceutical compositions |
| 06/30/2005 | WO2005058243A2 Methods for treating cancer using vascular endothelial cell growth inhibitor vegi-192a |
| 06/30/2005 | WO2005058233A2 Methods for treatment of acute pancreatitis |
| 06/30/2005 | WO2005058070A1 Peptides having an ace inhibiting effect |
| 06/30/2005 | WO2005058062A2 A process for inhibition of proteolytic activity during the ensiling of forages |
| 06/30/2005 | WO2005051328A3 Amelioration of macular degeneration and other ophthalmic diseases |
| 06/30/2005 | WO2005044989A3 Polynucleotides and polypeptides of anaplasma phagocytophilum and methods of using the same |
| 06/30/2005 | WO2005042560A3 Non-viral delivery of compounds to mitochondria |
| 06/30/2005 | WO2005028628A3 Modulation of eif4e expression |
| 06/30/2005 | WO2005026315A3 Method for producing insulin from a natural source and insulin |
| 06/30/2005 | WO2005025591A3 CASPASE DERIVED CARDs |
| 06/30/2005 | WO2005025494A3 Vaccine immunotherapy for immune suppressed patients |
| 06/30/2005 | WO2005023866A3 Peptides that inhibit complement activation |
| 06/30/2005 | WO2005023285A3 Agent and method for the treatment and prevention of tse and method for the production of said agent |
| 06/30/2005 | WO2005021022A3 Stable formulations of peptides |
| 06/30/2005 | WO2005017093A3 Polypeptides of streptococcus pyogenes |
| 06/30/2005 | WO2005012334A8 Biologically non-degradable peptide, angiotensin converting enzyme inhibitor, drug and functional food |
| 06/30/2005 | WO2005007193A3 Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor |
| 06/30/2005 | WO2004110392A3 Compositions and methods for treating coronavirus infection and sars |
| 06/30/2005 | WO2004103390A3 Stable analogs of peptide and polypeptide therapeutics |
| 06/30/2005 | WO2004103293A3 Modulators of the p2y10 receptor useful in altering t lymphocyte function |
| 06/30/2005 | WO2004096161A3 Pharmaceutical compositions for treating painful neuropathy and methods of treating same |